#North Africa Non-Invasive Prenatal Testing | Explore Tumblr posts and blogs

creative-news-alert · 10 months ago

Text

North Africa Non-Invasive Prenatal Testing Market Estimated to Witness High Growth Owing to Rising Demand for Early Diagnosis of Chromosomal Abnormalities and Fetal Development Monitoring

Non-invasive prenatal testing (NIPT) is a screening technique used to analyze DNA from a pregnant woman's blood sample to check the risk of chromosome abnormalities in her fetus. It is a non-invasive procedure that analyzes fetal DNA in the mother's bloodstream, allowing detection of such conditions as Down syndrome, without any risk to the pregnancy. NIPT has revolutionized prenatal testing by providing early and accurate screening with a high detection rate and low false positive rate, which has increased its demand and adoption globally.

The non-invasive prenatal testing market is estimated to be valued at US$ 3805.83 Bn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: One key driver behind the high growth of the North Africa non-invasive prenatal testing market is the rising demand for early diagnosis of chromosomal abnormalities and fetal development monitoring. NIPT allows detection of major chromosomal abnormalities such as Down syndrome and Trisomy 13 and 18 as early as nine weeks into pregnancy. This enables parents to cope better with the situation and seek necessary medical treatment or make informed reproductive choices. NIPT also helps monitor fetal growth and development with high accuracy and reliability. Growing awareness about the benefits of prenatal screening and diagnosis among expectant mothers and physicians in North African countries is significantly boosting adoption of NIPT. Further, technological advancements enabling more precise and rapid testing with simpler blood draws from pregnant women are fueling uptake of NIPT in the region. SWOT Analysis Strength: North Africa has a growing population with high birth rate which drives the demand for prenatal testing in the region. The governments are also promoting prenatal testing by offering subsidies. Favorable reimbursement policies from governments and insurance companies makes prenatal testing more affordable. Weakness: Lack of awareness about advanced prenatal screening tests is one of the challenges. Due to cultural and religious beliefs, some communities may be hesitant to adopt prenatal screening. Distance to health facilities in remote areas also poses accessibility issues. Opportunity: Rapid urbanization and growing medical tourism are opening new opportunities. Increasing investment from global players to expand services provides growth avenue. Rising female literacy and growing middle class will help create more awareness. Threats: Political instability in some countries creates uncertainty. Stringent regulations may delay new product launches or increase compliance costs for companies. Emerging low-cost alternatives from other regions can take away market share. Key Takeaways The North Africa Non-Invasive Prenatal Testing market size is expected to witness high growth. The non-invasive prenatal testing market is estimated to be valued at US$ 3805.83 Bn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024 to 2031.

Regional analysis comprises Egypt dominates the North Africa NIPT market currently accounting for over 30% market share owing to the large population and growing healthcare infrastructure in the country. Morocco and Algeria also have high potential and are projected to grow at over 8% during the forecast period driven by increasing awareness and expanding coverage. Key players operating in the North Africa Non-Invasive Prenatal Testing market are Enraf-Nonius B.V., DJO Global, EMS Physio Ltd., Dynatronics Corporation, A. Algeo Limited, BTL Industries, Inc., HMS Medical Systems, Whitehall Manufacturing, Patterson Companies, Inc., and Isokinetics, Inc. Enraf-Nonius B.V. and DJO Global collectively hold over 25% share owing to their robust product portfolio and widespread distribution network across the region. Emerging players are focusing on tie-ups with regional healthcare providers and launching affordable testing kits to gain market share.

Get more insights on this topic: https://www.newswirestats.com/north-africa-non-invasive-prenatal-testing-market-size-and-outlook/

#North Africa Non-Invasive Prenatal Testing #North Africa Non-Invasive Prenatal Testing Market #North Africa Non-Invasive Prenatal Testing Market size #North Africa Non-Invasive Prenatal Testing Market share #Coherent Market Insights

0 notes

healthcaremarketanalysis · 4 months ago

Text

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment.

Based on product & service, the liquid biopsy market has been segmented into assay kits, instruments, and services. The assay kits segment dominated the liquid biopsy market in 2023. The versatility of assay kits contributes to their market dominance. These kits are adaptable to various biomarkers and analytes, accommodating the diverse needs of liquid biopsy applications, from detecting circulating tumor DNA (ctDNA) to monitoring treatment response and disease progression.

The therapy selection segment held the largest share of the liquid biopsy market by clinical application segment in 2023.

Based on clinical applications, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. In 2023, the largest share of the liquid biopsy market was held by the therapy selection segment. The growth of therapy selection as the major clinical application segment is fueled by the advantages of liquid biopsy over traditional methods with its minimally invasive, real-time monitoring capabilities across various cancer types, its integration into clinical trials and drug development processes, and its cost-effectiveness in guiding therapy selection.

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Request Sample Pages:

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

#Liquid Biopsy Market #Liquid Biopsy Market Size #Liquid Biopsy Market Share #Liquid Biopsy Market Growth

0 notes

marketdevelopment · 8 months ago

Text

Liquid Biopsy Market Latest Innovations, Drivers and Industry Status 2023 to 2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

A liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing various biomarkers (such as circulating tumor cells, cell-free DNA, exosomes, and other nucleic acids) found in bodily fluids like blood, urine, or saliva. It's primarily used for the detection and monitoring of diseases, particularly cancer.

Advances in technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR have greatly enhanced the sensitivity and specificity of liquid biopsy tests, enabling more accurate detection and monitoring of diseases.

Liquid biopsies have gained particular attention in the field of oncology for early cancer detection, monitoring treatment response, and detecting resistance mutations. They offer a non-invasive alternative to tissue biopsies and can provide real-time information on tumor dynamics.

While oncology remains the primary focus of liquid biopsy applications, researchers and companies have been exploring its potential in other areas such as prenatal testing, infectious disease diagnostics, transplant monitoring, and autoimmune disease detection.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading players involved in the Liquid Biopsy Market include:

Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States), Beckman Coulter(United States), Illumina (United States), PerkinElmer (United States), Becton, Dickinson and Company (BD) (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Cancer Genetics, Inc. (United States), Myriad Genetics, Inc. (United States)

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years.

If You Have Any Query Liquid Biopsy Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/16300

Segmentation of Liquid Biopsy Market:

By Cancer Type

Lung

Breast

Liver

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cells

By End-User

Hospitals

Laboratories

Government Research Centre

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Key Reasons To Invest In Liquid Biopsy Market Report:

To provide a complete structure and a basic overview of the Liquid Biopsy market.

To provide insights into important Liquid Biopsy aspects such as growth trajectory, CAGR value, market share, and revenue analysis.

Assess growth opportunities, threats, market drivers, and associated risks.

To understand the Liquid Biopsy market competition by analysing the top business people along with market profiles, import/export details, revenue, profit, and market shares.

Indicate pricing structure, import/export details, supply chain analysis, SWOT analysis to facilitate key decision-making process.

Analysing emerging Liquid Biopsy market segments and sub-segments to drive ultimate growth, investment analysis, and future growth opportunities.

Understand sources of knowledge, intended research methodology, and important conclusions.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: [email protected]

#Liquid Biopsy #Liquid Biopsy Market #Liquid Biopsy Market Size #Liquid Biopsy Market Share #Liquid Biopsy Market Growth #Liquid Biopsy Market Trend #Liquid Biopsy Market segment #Liquid Biopsy Market Opportunity #Liquid Biopsy Market Analysis 2023

0 notes

report-1 · 1 year ago

Text

DNA Sequencing Platforms Market Size, Type, segmentation, growth and forecast 2023-2030

DNA Sequencing Platforms Market

The DNA Sequencing Platforms Market is expected to grow from USD 2.00 Billion in 2022 to USD 3.40 Billion by 2030, at a CAGR of 7.20% during the forecast period.

Get the Sample Report: https://www.reportprime.com/enquiry/sample-report/11008

DNA Sequencing Platforms Market Size

DNA sequencing platforms refer to the various technologies and equipment used for deciphering the genetic code in DNA samples. The DNA sequencing platforms market research report includes a market segment based on type, application, region, and market players. The types of DNA sequencing platforms include DNA microarray, DNA genotyping, and others. Applications of these platforms are in academic research institutions, medical research institutes, and others. The regional segment covers North America, Asia Pacific, Middle East, Africa, Australia, and Europe. The report profiles major market players such as Illumina, Thermo Fisher Scientific, Beckman Coulter, 454 Life Sciences Corporation, BGI, Appreciate the Beauty of Life, and Helicos. Regulatory and legal factors specific to market conditions are also discussed within the report. The DNA sequencing platforms market is expected to continue to expand globally as the importance of genetic data for both research and clinical applications becomes increasingly recognized.

DNA Sequencing Platforms Market Key Player

Illumina

Thermo Fisher Scientific

Beckman Coulter

454 Life Sciences Corporation

BGI

Buy Now & Get Exclusive Discount on this: https://www.reportprime.com/enquiry/request-discount/11008

DNA Sequencing Platforms Market Segment Analysis

The DNA Sequencing Platforms market refers to the market for technologies and services used for determining the sequence of nucleotides in a DNA molecule. The market is seeing strong growth, driven by factors such as increasing adoption of genomics in healthcare, pharmaceuticals, and academic research, growing demand for personalized medicine, and technological advancements.

The target market for DNA Sequencing Platforms is diverse and includes academic research institutions, pharmaceutical and biotechnology companies, clinical laboratories, hospitals, and government organizations. The academic research institutions segment is the largest and accounts for the majority of the revenue generated by the market, due to the wide and growing application of sequencing technologies in basic and translational research.

The major factors driving revenue growth of the DNA Sequencing Platforms market include increasing demand for personalized medicine and clinical genomics, declining costs of sequencing technologies and services, growing application of sequencing in agriculture and animal research, and increasing availability and adoption of high-throughput sequencing technologies.

The latest trends in the DNA Sequencing Platforms market include the emergence of new sequencing technologies, such as nanopore sequencing and single-cell sequencing, increasing adoption of cloud-based bioinformatic solutions, and growing interest in non-invasive prenatal testing.

The major challenges faced by the DNA Sequencing Platforms market include concerns over data privacy and security, ethical and regulatory issues related to the sequencing of human genomes, and the need to develop and validate clinical applications of sequencing technologies.

The main findings of the report suggest that the DNA Sequencing Platforms market is poised for strong growth in the coming years, driven by the growing adoption of sequencing technologies in healthcare and research, and the emergence of new and innovative sequencing platforms. The report recommends that market players focus on developing and commercializing new sequencing technologies, expanding their service offerings, and forging strategic partnerships to enhance their market presence. Additionally, they should work closely with regulators and stakeholders to build trust and confidence in the technology and ensure that ethical and regulatory concerns are adequately addressed.

This report covers impact on COVID-19 and Russia-Ukraine wars in detail.

Purchase This Report: https://www.reportprime.com/checkout?id=11008&price=3590

Market Segmentation (by Application):

Academic Research Institution

Medical Research Institute

Other

Information is sourced from www.reportprime.com

#business #market research #market growth #market analysis #market strategies

0 notes

sophiareddy123 · 1 year ago

Text

The Non-invasive Prenatal Testing Market is Segmented by Component (Instruments, Kits and Reagents, Services), Application (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Other Applications), End User (Hospitals, Diagnostic Labs), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Download Free Sample Report - Non-invasive Prenatal Testing Market

#marketresearchreports #researchreports #industryreports

0 notes

delvenservices · 1 year ago

Text

Next Generation Sequencing (NGS) Market Growth Opportunities & Key Players

Next Generation Sequencing (NGS) Market, by Product (Consumables, Platforms, Services and Nerve Blockers), Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Agriculture and Animal Research, and Other Applications), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, and Other Technologies), and End User (Academic and Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End Users) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Market Overview

The global Next Generation Sequencing (NGS) market size was estimated at USD 11.59 billion in 2023 and is projected to reach USD 29.84 billion in 2030 at a CAGR of 14.47% during the forecast period 2023-2030.

Next-generation sequencing (NGS) is a massively parallel sequencing method that offers scalability, high throughput, and high speed for genome-wide sequencing of nucleotides. Because it involves the preparation of material for the subsequent sequencing reaction, DNA presequencing is one of the most important processes in a common sequencing protocol. Globally, NGS is increasingly integrated into clinical laboratory analysis, testing and disease diagnosis in the healthcare industry. In pharmacogenomics, next-generation sequencing (NGS) is often used to accelerate the drug discovery process.

The growth of the global next-generation sequencing market is primarily driven by the growth of genome mapping programs; proliferation of next-generation sequencing applications; rising health care costs; and technological advances in sequencing platforms. For example, in 2019, Thermo Fisher Scientific, a world leader in scientific services, launched a new generation platform, the Ion Torrent Genexus System, which provides sample for one-day reporting. Additionally, Agilent Technologies, Inc., an American analytical development and manufacturing company, brought in 2019, we launched the Magnis NGS Prep System, a next-generation sequencing library preparation system designed to perform complex sequencing analyzes at the push of a button. Fetal genetic makeup and configuration can be detected with NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT). R&D-related NGS has risen to new heights thanks to investments in NGS technologies worldwide. Growing demand for genome mapping software and increasing use of NGS is fueling market growth

During the COVID-19 pandemic, governments around the world partnered with the private sector to bring NGS technology to market as a potential diagnostic tool. The NGS diagnostic technique was able to determine the genetic sequence of the virus and helped researchers figure out how mutations occur. Next-generation sequencing (NGS) has been used to study COVID-19, making it much easier to trace the origin of SARS-CoV-2.

To Understand Business Strategies, Request for a Sample Report at: https://www.delvens.com/get-free-sample/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Delvens Industry Expert's Standpoint

The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak Declining sequencing costs have increased the use of NGS in disease diagnosis. Various testing kits and testing services are emerging for the non-invasive prenatal testing, cancer diagnosis, genetic testing and more, leading the global market. In addition, active support from the government through product approval and improvement of reimbursements for such diagnostic tests is expected to provide new opportunities for market growth. Additionally, increasing prevalence of chronic diseases, increase in research and initiation of high-budget genomics projects are expected to boost market growth during the forecast period. These factors have led to the expansion of the market and increased demand for Next Generation Sequencing (NGS) solutions.

Key Findings

The application segment is further fragmented into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, agriculture & animal research, and other applications. The biomarker and cancer segment is expected to account for a larger market size during the forecast period due to increase in prevalence of cancer and advancement in technology in next generation sequencing. However, the personalized medicine segment is expected to witness considerable next generation sequencing market growth during the forecast period, due to surge in demand for drug treatment, advancement in R&D in healthcare sector, and rise in awareness for NGS testing in pharmaceutical and biotechnological industry.

The product type segment is further bifurcated into Consumables, Platforms, Services and Nerve Blockers. The consumables segment is the largest market during the forecast period owing to development of technology in molecular genetics and surge in demand for novel pre-sequencing products and kits that execute DNA fragmentation, target enrichment, size selection, and others. However, the services segment is expected to witness considerable next generation sequencing market growth during the forecast period, due to advancement in technology based on SMRT sequencing, and increase in application of cloud computing for NGS data storage.

The end user segment is further bifurcated into Academic and Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End Users. Academic & clinical research to account for a larger market size during the forecast period due to increase in application-based usage in these institutes and rise in oncology research. However, the pharmaceutical & biotechnology companies’ segment is expected to witness considerable market growth during the forecast period, due to increase in prevalence of chronic disease, and advancement in R&D in the next generation sequencing market for therapeutics, oncology, and genomics research.

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, increasing number of genomics research projects, rising demand for new NGS platforms and growing use of NGS consumables are various factors projected to drive the growth.

To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period. In North America, increasing number of genomics research projects, rising demand for new NGS platforms and growing use of NGS consumables are various factors projected to drive the growth.

Competitive Landscape

10X Genomics

Agilent Technologies

BGI Group

Bio-Rad Laboratories Inc.

Brooks Automation Inc.

CD Genomics

DNASTAR Inc.

Eurofins Scientific

F. Hoffmann-La Roche Ltd.

Illumina Inc.

Macrogen Inc.

New England Biolabs

Novogene Corporation Inc.

Oxford Nanopore Technologies

Pacific Biosciences of California Inc.

PerkinElmer Inc.

Precigen Inc., (Intrexon Bioinformatics Germany GmbH)

Promega Corporation

Psomagen

Qiagen

Takara Bio

Tecan Trading Group

Thermo Fisher Scientific Inc.

Zymo Research

Recent Developments

In January, 2023, QIAGEN announced a strategic partnership with California-based population genomics leader Helix to advance next-generation sequencing companion diagnostics in hereditary diseases.

In March, 2023, The company SOPHiA GENETICS announced a new partnership with Qiagen that will pair QIAseq reagent technology with the DDM platform to enhance tumor analysis through next-generation sequencing (NGS).

Direct Purchase of Research Report at: https://www.delvens.com/checkout/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.

Gain authentic and granular data access for the Next Generation Sequencing (NGS) Market to understand the trends and the factors involved in changing market situations.

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The Next Generation Sequencing (NGS) Market is segmented into various segments such as product, application, technology, end-user and region:

Based on Product

Consumables

Sample Preparation Consumables

DNA Fragmentation, End Repair, A-Tailing and Size Selection

Library Preparation & Target Enrichment

Quality Control

Other Consumables

Platforms

HiSeq

MiSeq

Ion Torrent

Solid

Pacbio Rs II and Sequel System

Other Sequencing Platforms

Services

Sequencing Services

RNA Sequencing

Whole Exome Sequencing

Whole Genome Sequencing

Targeted Sequencing

Chip Sequencing

De Novo Sequencing

Methyl Sequencing

Data Management Services

NGS Data Analysis Services

NGS Data Analysis Software & Workbenches

NGS Storage, Management and Cloud Computing Solutions

Based on Application

Diagnostics

Biomarkers and Cancer

Reproductive Health

Personalized Medicine

Agriculture and Animal Research

Other Applications

Based on the Technology

Sequencing by Synthesis

Ion Semiconductor Sequencing

Sequencing by Ligation

Pyrosequencing

Single Molecule Real Time Sequencing

Other Technologies

Based on End User

Academic and Research Centers

Pharmaceutical and Biotechnology Companies

Hospitals and Clinics

Other End Users

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

[email protected]

0 notes

reportsneww · 2 years ago

Text

Non-Invasive Prenatal Testing (NIPT) Market size 2023

Newark, New Castle, USA – Growth Plus Reports’ most recent study examines the Global Non-Invasive Prenatal Testing (NIPT) Market’s production, prospective uses, demand, key companies, and SWOT analysis.

The Non-Invasive Prenatal Testing (NIPT) Market Report will help you determine the best distribution strategies for specific products and identify potential markets. In addition, the report examines the purchasing and supply patterns that impact the market. The Non-Invasive Prenatal Testing (NIPT) market research report provides insights into the limitations, market trends, prospects, drivers, and competition in the Non-Invasive Prenatal Testing (NIPT) sector.

You may get insights into the TOC, and Statistics for essential facts, information, trends, and competitive landscape information.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/non-invasive-prenatal-testing-nipt-market/8147

The following are the leading companies in the Global Non-Invasive Prenatal Testing (NIPT) market:

YOURGENE HEALTH Plc

Illumina, Inc.

Natera, Inc.

Hoffmann-La Roche AG

Perkin Elmer Inc.

Laboratory Corporation of America Holdings

Eurofins

LifeCodexx GmbH

Progenity, Inc.

Quest Diagnostics Incorporated

Medgenome, Inc.

Growth Plus Reports studies the key trends in each category and sub-segment of the Non-Invasive Prenatal Testing (NIPT) market, along with Global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

SEGMENTATION

GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET – ANALYSIS & FORECAST, BY PRODUCTS & SERVICES

Instruments

Ultrasound Devices

Next-Generation Sequencing Systems

Polymerase Chain Reaction Instruments

Microarrays

Consumables

Assay Kits & Reagents

Disposables

Services

GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET – ANALYSIS & FORECAST, BY METHOD

Ultrasound Detection

Biochemical Screening Testing

Cell-Free DNA Maternal Plasma Tests

GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET – ANALYSIS & FORECAST, BY APPLICATION

Trisomy

Microdeletion Syndrome

Others

GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET – ANALYSIS & FORECAST, BY END-USER

Diagnostic Laboratories

Hospitals

For More Information or Query or Customization visit: https://www.growthplusreports.com/inquiry/customization/non-invasive-prenatal-testing-nipt-market/8147

Companies may utilize Non-Invasive Prenatal Testing (NIPT) market report to get insights on market variables and any restraints that may affect the manufacturing of their product. Companies that are expanding abroad require thorough Global market research that includes real market data to assist with their marketing strategy. This Global market Non-Invasive Prenatal Testing (NIPT) industry study analyzes important market dynamics and provides in-depth information and statistics to help companies flourish. This research report on the Non-Invasive Prenatal Testing (NIPT) market takes advantage of advanced and professional approaches such as SWOT analysis and GRG Health’s unique GrowthMIX strategy.

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Non-Invasive Prenatal Testing (NIPT) Market TOC:https://www.growthplusreports.com/report/toc/non-invasive-prenatal-testing-nipt-market/8147

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

QUICK BUY: https://www.growthplusreports.com/checkout-8147

Browse Latest Healthcare Reports:

MOG Antibody Associated Disorders Treatment Market Size, Share 2023 to 2031

Aortic Valve Replacement Devices Market Industry Analysis report to 2031

Alveolar Soft Part Sarcoma Market size, share & trends Analysis report to 2031

Magnetic Resonance Imaging Equipment Market Developments

Facet Joint Injections Market Size, Share & Regional Outlook to 2031

Health Telemetry Market size, Technology & Industry Analysis report to 2031

Blood Cancer Diagnostics Market Size, Share Industry Analysis to 2031

Smoking Cessation Apps Market size, share & trends Analysis report to 2031

Serotonin-Dopamine Activity Modulators Market Size, Share 2023 to 2031

0 notes

healthcare-market · 3 years ago

Text

TMR Analyzes Impact of Outbreak of COVID-19 on Amniocentesis Needle Market

Amniocentesis is a prenatal test also known as amniotic fluid test or AFT. It is carried out to diagnose the chromosomal abnormalities and fetal infections. It is also used for sex determination. Amniocentesis involves removal of a small amount of amniotic fluid, which contains fetal tissues, from the sac surrounding the fetus. Amniotic fluid has cells and other substances that can give evidence about the health of fetus. An amniocentesis needle is used to withdraw amniotic fluid precisely. Amniocentesis needles are sterile and intended for single use. The amniocentesis needle tip has a spiral engraving to offer clear visibility under ultrasound guidance. The needle is placed into the amniotic sac away from both baby and the placenta to withdraw amniotic fluid. Direct fetal injuries during an amniocentesis is rare; however, some risk in involved in the whole amniocentesis procedure. Amniocentesis technique can lead to severe complications such as amniotic fluid leakage and contractions, but it is quite rare and uncommon. It occurs after the procedure in 1% to 2% of cases.

Read Report Overview: https://www.transparencymarketresearch.com/amniocentesis-needle-market.html

Increase in pregnancy rate, rise in preference for non- and minimally-invasive diagnostic procedures, high adoption and acceptance of diagnostic test in developed markets, high success rate of amniocentesis procedure, and innovations and developments in technology drive the global amniocentesis needle market. Major restraints of the market are fetal injuries, stiff competition among existing players, and high cost of the procedure. Additionally, low availability of diagnostic equipment and lack of awareness of amniocentesis technique among the rural population in developing and underdeveloped economies.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39425

The global amniocentesis needle market can be segmented based on product type, application, end-user, and region. In terms of product type, the market can be categorized based on size of needle i.e., 100–150 mm, larger than 150 mm, and smaller than 100 mm. 100–150 mm needles are most commonly used for amniocentesis diagnostic test due to rising awareness about of the amniocentesis technique to detect and diagnose the abnormalities or health of the developing fetus is likely to boost the overall market. Based on application, the global amniocentesis needle market can be classified into amniocentesis, amnioreduction, fetal blood transfusion, amnioinfusion, cordocentesis, and others. End-users of amniocentesis needles are hospitals, diagnostic centers, clinics, and others. The hospitals segment is likely to hold the largest market share of the amniocentesis needle market due to easy accessibility and availability of fast test results in hospitals.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=39425

Geographically, the global amniocentesis needle market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest market share, followed by Europe. The U.S. accounted for a major share of the global amniocentesis needle market in North America. Advanced technology, high awareness level, and high purchasing power in North America drive the amniocentesis needle market. However, high cost of the test restrains the market in developing regions. Nevertheless, the market in Asia Pacific has witness high growth rate in the past few years. Rise in population, surge in disposable income, increase in population, and rise in awareness are the key factors driving the market in Asia Pacific. Therefore, the region has witnessed high number of new entrants compared to developed regions.

Pre-book Amniocentesis Needle Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=39425&ltype=S

Major players in the global amniocentesis needle market include Becton, Dickinson and Company, Medtronic, CooperSurgical, Inc., Smiths Group plc, Medline Industries, Inc., Cook Group, Rocket Medical plc, RI.MOS. srl, Biopsybell srl, and Tsunami Medical Srl.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/players-in-pressure-relief-devices-market-lean-on-launching-smart-therapeutic-beds-for-preventing-pressure-injuries-in-patients-market-valuation-to-reach-us-4-54-bn-by-2030--finds-tmr-301349292.html

https://www.prnewswire.com/news-releases/urgent-care-centers-market-valuation-to-reach-us-35-4-bn-by-2027-due-to-increased-access-to-healthcare-low-cost-of-treatment-finds-a-tmr-study-301355857.html

https://www.prnewswire.com/news-releases/rise-in-prevalence-of-dry-eye-disease-due-to-ageing-use-of-computers-to-drive-dry-eye-disease-treatment-market-says-tmr-301360562.html

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Mr. Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected]

Website: https://www.transparencymarketresearch.com/

0 notes

tmr123123 · 3 years ago

Text

Non-invasive Prenatal Testing (NIPT) Market 2021 Recent Developments, Segmented Data and Business Operation Data Analysis by 2030

Trends Market Research has introduced the addition of a new report entitled Global Non-invasive Prenatal Testing (NIPT) Market Growth 2021-2027 includes the regional and global market facts, which is estimated to acquire moneymaking valuation over the forecast length from 2021 to 2027. The file explains the market definition, classifications, applications, engagements, and global Radon Fans enterprise developments are.

The report provides an understanding of the industry competitors; the assessment consists of the market shares of the competitors, as well as the market developments, demands, drivers, opportunities, demanding situations, product analysis. The sales channel, growth potential, potentially disruptive trends, industry product innovations, and the value/volume of size, market segments. Current market developments and dynamics helps in mapping the track of the global Non-invasive Prenatal Testing (NIPT) Market.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.trendsmarketresearch.com/report/sample/9844

According to TMR Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24–25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and presence of huge population base.

The report then focuses on the countries and regions of the globe, which presents the regional popularity of the market, including extent and value, market size, and price structure. Leading players of the global Non-invasive Prenatal Testing (NIPT) Market are investigated, organizations, consolidations or acquisitions, and markets served.

Non-invasive Prenatal Testing Market by Application:

Trisomy

Microdeletion Syndrome

Other NIPT Applications

The report additionally gives the global significant driving industry players of the market, for example, value, enterprise profiles, revenue, determination, creation, and contact data. The document suggests a portrayal of the geographical quantity of the global Non-invasive Prenatal Testing (NIPT) Market.

The countries covered in the market report are:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Direct Purchase this Market Research Report Now @ https://www.trendsmarketresearch.com/checkout/9844/Single

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The research report has used the numbers and figures in a comprehensive way with the assist of graphical and pictorial representation, which represents more clarity at the global Non-invasive Prenatal Testing (NIPT) Market. The data factors such as the flow patterns, openings, drivers, restrictions, and information are accumulated through authentic sources for future plans for the industry.

Significance of the Report Which Makes It worth Buying:

A broad and precise understanding of the global Radon Fans industry is offered in the segmented form based on product types, applications, and regions

Understand the industry delivery chain with a deep dive on the value augmentation.

Understand the specific dynamics influencing the market – key using factors, challenges, and hidden opportunities.

Get Discount On The Purchase Of This Report @ https://www.trendsmarketresearch.com/report/discount/9844

0 notes

researchnesterinsights · 3 years ago

Text

Non-Invasive Prenatal Testing Market- Analysis by Size, Share Latest Global Trends, Development, Future Growth, Revenue Forecast, Demand Forecast to 2027

Recent report Published by Research Nester titled “Non-Invasive Prenatal Testing Market: Global Demand Analysis & Opportunity Outlook 2027” delivers the detailed overview of the global non-invasive prenatal testing market in terms of market segmentation by product type, by test type, by method, by application, by end user and by regions

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global non-invasive prenatal testing market can be segmented on the basis of product type, test type, method, application, end user and regions. Based on product type, it is sub-segmented into consumables, disposables, assay kits & reagents, next-generation sequencing system, PCR instruments, ultrasound devices, microarrays and others; test type into MaterniT21 PLUS, NIFTY, harmony test, PrenaTest, panorama test, verifi, and others. On the basis of method, it is sub-segmented into cell-free DNA in maternal plasma tests, biochemical screening tests, ultrasound detection & fetal cells in maternal plasma tests. On the basis of application, it is sub-segmented into microdeletion detection, trisomy detection & others.

Get a Sample Copy of this Report with Graphs and Charts: https://www.researchnester.com/sample-request-1396

On the basis of end user, it is sub-segmented into diagnostic laboratories and hospitals. MaterniT21 PLUS is expected to lead the test type segment during the forecast period. The non-invasive prenatal testing industries across the globe are focusing on helping doctors to detect genetic abnormalities in the early stage which is further estimated to boost the growth of the market.

The non-invasive prenatal testing market is anticipated to record a CAGR of around 17.5% over the forecast period i.e. 2019-2027. Increasing incidence rate of Down’s syndrome coupled with rising number of women opting for late pregnancy are some of the major factors which are anticipated to boost the growth of the market. Further, growing preference for non-invasive techniques coupled with increasing technological advancements are expected to support the growth of the market over the forecast period.

Regionally, global non-invasive prenatal testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Among these regions, North America is expected to dominate the global non-invasive prenatal testing market on account of increasing incidence of chromosomal abnormalities, growing technological developments, rising healthcare expenditure along with growing rate of late pregnancy.

Further, the Asia Pacific region is also expected to have a substantial market share on the back of increasing awareness among people regarding chromosomal abnormalities, advanced maternal age and rapidly growing healthcare sector.

Growing Rate of Women opting for Late Pregnancies to Augment the Market Growth

Many women are becoming first time mothers at the age of 35 or older. Most of the child births take place in women between the ages of 30 and 40. The rising number of women opting for late pregnancy coupled with growing incidence of Down’s syndrome are the major factors which are expected to fuel the growth of the market over the forecast period.

However, strict regulations enforced by the government such as following of specific norms for delivering quality medical devices and to maintain appropriate accuracy are expected to restraint the growth of the market.

This report also provides the existing competitive scenario of some of the key players of the global non-invasive prenatal testing market which includes company profiling of key companies such as F. Hoffmann-La Roche Ltd., E Healthcare, Koninklijke Philips N.V., Pacific Biosciences of California, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., Agilent Technologies, Inc., Berry Genomics Co. Ltd., Illumina Inc., Quest Diagnostics Incorporated and other prominent players.

Get a Sample PDF Report Here- https://www.researchnester.com/sample-request-1396

The outlining enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global non-invasive prenatal testing market that is expected to help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

About Research Nester:

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 591

#Non-Invasive Prenatal Testing Market #Non-Invasive Prenatal Testing Market Analysis

0 notes

healthcaremarketanalysis · 4 months ago

Text

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

North America is the largest regional market for liquid biopsy market.

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report provides insights on the following pointers:

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

#Liquid Biopsy Market #Liquid Biopsy Market Size #Liquid Biopsy Market Share #Liquid Biopsy Market Growth

0 notes

marketdevelopment · 8 months ago

Text

Liquid Biopsy Market Size-Share, Growth Factors, Forecast 2023-2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

The liquid biopsy market has been witnessing significant growth due to its non-invasive nature and its potential to revolutionize cancer diagnostics and treatment monitoring. Liquid biopsy involves the analysis of biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, extracted from bodily fluids like blood and urine. Traditional tissue biopsies are invasive and often provide limited information about tumor heterogeneity, making liquid biopsy an attractive alternative for cancer detection and monitoring.

Factors driving the growth of the liquid biopsy market include advancements in genomic technologies, increasing prevalence of cancer worldwide, rising demand for personalized medicine, and growing awareness about the benefits of early cancer detection. Additionally, the liquid biopsy market is propelled by ongoing research and development activities aimed at enhancing the sensitivity and specificity of liquid biopsy tests, as well as expanding their applications beyond cancer diagnosis to areas such as prenatal testing and organ transplantation monitoring.

Request Sample Copy@:

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading Key Players Covered Liquid Biopsy Market: -

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), BIOCEPT Inc. (the US), Illumina Inc. (the US), Angle plc (UK), Oncimmune(UK), Lucence health Inc. (US), FreenomeHoldings Inc. (US) and Other Major Players.

Segmentation of Liquid Biopsy Market: -

By Cancer Type

By Circulating Biomarker

By End-User

Market Segment by Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

If You Have Any Queries Regarding Liquid Biopsy Market, Please Visit:

https://introspectivemarketresearch.com/inquiry/16300

Owning our reports (For More, Buy Our Report) will help you solve the following issues:

1. Uncertainty about the future?

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.

2. Understanding market sentiments?

It is imperative to have a fair understanding of market sentiments for a strategy. Our insights furnish you with a hawk-eye view on market sentiment. We keep this observation by engaging with Key Opinion Leaders of a value chain of each industry we track.

3. Understanding the most reliable investment centers?

Our research ranks investment centers of the market by considering their returns, future demands, and profit margins. Our clients can focus on the most prominent investment centers by procuring our market research.

4. Evaluating potential business partners?

Our research and insights help our clients in identifying compatible business partners.

Acquire This Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to helping our clients grow and successfully impact the marketplace. Our team at IMR is ready to help our clients grow their businesses by offering strategies to achieve success and monopoly in their respective fields. We are a global market research company, specializing in the use of big data and advanced analytics to gain a broader picture of market trends. We help our customers to think differently and build a better tomorrow for all of us. As a technology-driven research company, we consider extremely large data sets to uncover deeper insights and provide conclusive consulting. We don't just provide intelligence solutions, we help our clients achieve their goals.

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1049

Email: [email protected]

#Liquid Biopsy Market #Liquid Biopsy Market Size #Liquid Biopsy Market Share #Liquid Biopsy Market Growth #Liquid Biopsy Market Trend #Liquid Biopsy Market segment #Liquid Biopsy Market Opportunity #Liquid Biopsy Market Analysis 2022 #US Liquid Biopsy Market #Liquid Biopsy Market Forecast #Liquid Biopsy Industry #Liquid Biopsy Industry Size

0 notes

preranajoshi1096 · 3 years ago

Text

Thalassemia Treatment Market Size, Share | Industry Research Report, 2021-2027 | Covid-19 Impact Analysis

Global Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Thalassemia Treatment Market Reports –

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (β4) called Hemoglobin H.

Get Sample Copy for Thalassemia Treatment Market Report for 2021 @ https://brandessenceresearch.com/requestSample/PostId/48

Key Players –

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Market Dynamics –

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.2±2.2. Average 18.5%±14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin Regional Analysis –

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

Key Benefits for Market Reports –

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.

Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Thalassemia Treatment Market report helps to identify opportunities in market place.

Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.

Thalassemia Treatment Market Segmentation–

By Type of Treatment Analysis - Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy, Other

By Diagnosis Analysis - Perinatal Testing, Prenatal Testing, Pre-Implantation, Other

By End user Analysis - Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries, Other

By Regional & Country Analysis

North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Thalassemia Treatment Market Key Players-

Bluebird bio Inc.

Acceleron Pharma Inc.

Novartis AG

Celgene Corporation

Shire plc

Bellicum Pharmaceuticals

GlaxoSmithKline Plc

Celgene

Lonza group

Alnylam Pharmaceuticals Inc.

Calimmune Inc.

CRISPR Therapeutics

Editas Medicine Inc.

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

#Thalassemia Treatment Market #Thalassemia Treatment Market 2021 #Thalassemia Treatment Market Size #Thalassemia Treatment Market Share

0 notes

healthcare-market · 3 years ago

Text

Amniocentesis Needle Market Size will Grow Profitably in the Near Future

Read Report Overview: https://www.transparencymarketresearch.com/amniocentesis-needle-market.html

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39425

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=39425

Pre-book Amniocentesis Needle Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=39425&ltype=S

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/urgent-care-centers-market-valuation-to-reach-us-35-4-bn-by-2027-due-to-increased-access-to-healthcare-low-cost-of-treatment-finds-a-tmr-study-301355857.html

https://www.prnewswire.com/news-releases/rise-in-prevalence-of-dry-eye-disease-due-to-ageing-use-of-computers-to-drive-dry-eye-disease-treatment-market-says-tmr-301360562.html

About Us

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

adityarana1687-blog · 3 years ago

Text

Preimplantation Genetic Testing Market Expected To Have A $107.3 Million Valuation By 2024

The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market

Further key findings from the report suggest:

Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018

Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future

Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018

Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment

Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy

Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures

Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries

Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others

Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Grand View Research has segmented the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market on the basis of PGD/PGS, type, application, and region:

Preimplantation Genetic Testing (PGT) PGD/PGS Outlook (Revenue, USD Million, 2014 - 2024)

Preimplantation Genetic Diagnosis (PGD)

Preimplantation Genetic Screening (PGS)

Preimplantation Genetic Testing (PGT) (PGS/PGD) Type Outlook (Revenue, USD Million, 2014 - 2024)

Chromosomal Abnormalities

X-linked Diseases

Embryo Testing

Aneuploidy Screening

HLA Typing

Other PGT Types

Fresh Embryo (Own Eggs)

Frozen Embryo (Own Eggs)

Fresh Embryo (Donor Eggs)

Frozen Embryo (Donor Eggs)

Preimplantation Genetic Testing (PGT) (PGS/PGD) Application Outlook (Revenue, USD Million, 2014 - 2024)

Embryo HLA typing for stem cell therapy

IVF Prognosis

Late Onset Genetic Disorders

Inherited Genetic Disease

Others

Preimplantation Genetic Testing (PGT) (PGS/PGD) Regional Outlook (Revenue, USD Million, 2014 - 2024)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa (MEA)

U.S.

Canada

Germany

U.K.

Spain

Belgium

Czech Republic

Poland

Sweden

Finland

Norway

Netherlands

Italy

Japan

China

India

Singapore

Malaysia

Brazil

Mexico

Argentina

Chile

South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

#Preimplantation Genetic Testing Market

0 notes

jesse-pinkman123 · 3 years ago

Text

Genomics Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Genomics Market by Product Type (Consumables, Software, and Others), by Technology (PCR, Microarray, Next Gene Sequencing, Nucleic Acid Extraction and Purification, and Others), by Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture & Animal Research, and Others), by End Users (Academic and Research Institute, Pharmaceutical & Biotechnology Companies, Hospital and Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

Genomics is the study of human genes and chromosomes. It focuses on structure, function, evolution, mapping, and editing of genomes. Genome is the genetic material of organism, which includes the Deoxyribonucleic acid (DNA). DNA consists the information needed to build the whole human body. Human genome consists of 23 pairs of chromosomes and 24000 genes. This study is divided into various types such as structural genomics, functional genomics, and comparative genomics.

Global Genomics Market Drivers

Increasing new product launches is expected to drive the global genomics market growth. For instance, in January 2019, Contextual Genomics launched two molecular hotspot assays (Liquid Biopsy Test and updated Solid Tumor Panel) for the detection of genomic mutations in blood and solid tumors.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2660

Furthermore, in May 2015, Rosetta Genomics Ltd. launched OncoGxOne. It is Next Generation Sequencing (NGS) test that profiles tumors for targeted therapy selection and chemotherapeutic tolerance.

Moreover, in September 2018, Zenome launched the first decentralized genomic internet software, which is expected to increase possibilities of safe storage of large amount of genetic data. The main advantage of decentralized genomic internet software is that the degree of security is much higher.

Global Genomics Market Restraints

Lack of qualified and trained professionals in genomics study is a major challenge for the global genomics market growth. For instance, in January 2019, according to express healthcare report, genomics study needs highly qualified and trained professionals to optimize lab workflows and run it efficiently.

Global Genomics Market Regional Analysis

Europe is expected to gain significant share in the global genomics market over the forecast period, owing to increasing launches of new products by key players. For instance, in April 2017, Illumina, Inc. announced launch of its new product VeriSeq NIPT Solution, it is a CE-IVD marked next-generation sequencing (NGS)-based approach to non-invasive prenatal testing (NIPT).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/genomics-market-2660

This approach includes the CE-IVD marked library preparation and analysis software. This software enables fast, highly accurate, cost-effective, and non-invasive parenteral testing (NIPT).

Furthermore, Asia Pacific is also projected to witness significant growth in the global genomics market during the forecast period, owing to increasing collaboration activities by key players. For instance, in January 2018, 10X Genomics, Inc. collaborated with the Berry Genomics Co. Ltd. Under this collaboration, 10x Genomics, Inc. focuses on development of approaches for next generation non-invasive prenatal testing (NIPT) and developing and offering new services for Berry Genomics Co. Ltd.

Key players operating in the global genomics market include Thermo Fisher Scientific, Inc., Agilent Technologies, Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences, Oxford Nanopore Technologies., 23andMe, Inc., Foundation Medicine, Inc. Hoffmann-La Roche Ltd., and Myriad Genetics, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2660

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Genomics Market Analysis #Genomics Market

0 notes